Introduction
The progressive growth of a malignant tumor requires an adequate blood supply, which is provided by newly formed vessels. Abundant evidence supports the concept that this pathological neovascularization is mostly induced by angiogenic factors of tumor origin (Klagsbrun and D'Amore, 1991; Folkman and Shing, 1992) . The production of several angiogenic factors by a speci®c tumor cell type, and the presence on endothelial cells of a variety of angiogenic factor receptors, suggest that angiogenesis is determined by combinations of interacting stimuli. Among the angiogenic factors, the VEGF (Vascular Endothelial Growth Factor) family displays several properties suggesting a crucial function in tumor angiogenesis (for review see Ferrara, 1993a) . VEGF has been isolated from several tumor cell lines (Senger et al., 1983; PloueÈ t et al., 1989; Rosenthal et al., 1990; Conn et al., 1990a,b) . VEGF synthesis is dramatically upregulated in high-grade gliomas, de®ned by prominent endothelial cell proliferation (Plate et al., 1992) . Hypoxia, a common feature of the tumor cell microenvironment also increases VEGF mRNA levels (Shweiki et al., 1992) . Anti-VEGF antibodies have been shown to inhibit the growth of several tumorigenic cell lines in nude mice .
The VEGF family comprises secreted homodimeric proteins encoded by a single gene (Tisher et al., 1991) . Alternative splicing of VEGF pre-mRNA leads to at least three peptides of 121, 165 and 189 amino acids. VEGF 206 is a rare form generated by an additional 17-amino acid insertion at position 116, only identi®ed in a human fetal liver cDNA library (Houck et al., 1991) . Each VEGF isoform promotes the growth of endothelial cells, in vitro. The alternative splicing of the VEGF pre-mRNA however markedly regulates VEGF bioavailability: the short form (VEGF 121) is freely soluble, while the longer forms (VEGF 189 and 206) are sequestered in cell membranes and the extracellular matrix. VEGF 165 has an intermediate secretion pattern, both freely diusible and cell membrane bound .
Two tyrosine kinase receptors, products of the¯t and KDR/¯k-1 genes, have been identi®ed as VEGF receptors (DeVries et al., 1992; Terman et al., 1992; Quinn et al., 1993; Millauer et al., 1993) . The signals transduced by the¯t-1 receptor still remain unclear. The activation of KDR receptor induces mitogenicity in endothelial cells (Waltenberger et al., 1994) . Although VEGF activity is mainly restricted to endothelial cells, we recently reported a VEGF autocrine loop in human retinal pigment epithelial (RPE) cells (Guerrin et al., 1995) .
In the present study, we describe the eects of the introduction of an expression vector that directs constitutive VEGF synthesis into rat RPE cells. The transfected cells were characterised for their ability to grow in an anchorage-dependent and -independent fashion. We report that the constitutive expression of VEGF 165 results in a cell growth advantage. Moreover, in the presence of ®broblast growth factor-2 (FGF-2) the transfected cells exhibit a transformed phenotype. Analysis of FGF receptors indicated that such cells overexpress ®broblast growth factor receptor-1 (FGFR-1). Most probably, FGFR-1, which is a high anity receptor for FGF-2 (Dionne et al., 1990) , mediates the transforming eect induced by this growth factor.
Results

Generation of cell lines expressing VEGF
The expression vector was used to transcribe both the cDNA encoding the 165 amino acid form of the human VEGF (V165) and the Neo resistance gene under the control of a CMV promoter, as a polycistronic RNA molecule. This plasmid was introduced by the calcium phosphate method into rat RPE cells. Control cultures were transfected with a plasmid containing the bacterial CATcDNA in place of VEGF. Clones resistant to 0.4 mg/ml Geneticin (G418) were selected for 2 weeks. For each construction actively growing colonies were isolated and expanded as described in Materials and methods.
Expression of VEGF and FGF2 in transfected rat RPE cells
To investigate the expression of the V165 in control and VEGF transfected RPE rat cells, randomly primed ®rst-strand cDNAs were prepared and ampli®ed with human VEGF primers I and II (Table 1) . Due to the conservation of VEGF cDNA sequences between human and rat, the RT ± PCR ampli®cation from both transfected human cDNA and endogenous rat gene was expected. Therefore, control ampli®cations were performed with cDNAs from cells stably transfected with the pR-EN-CAT. We also took advantage of a unique NcoI site in exon 2 of human VEGF gene, which is not conserved in the rat, so that the extensive digestion of RT ± PCR products with NcoI generated smaller fragments from the human products, but left the rat products unaected. Two bands (453 and 587 bp) of similar intensity were observed with rat control cells, the size of which was unaected by NcoI digestion (Figure 1) . Fragments of the same sizes were obtained with human RPE cells. After NcoI digestion a band of 494 bp was generated, corresponding to the V165 mRNA. Disappearance of the band of 453 bp indicated the complete digestion with NcoI. A constitutive expression of the human V165 mRNA was observed in pR-EN-V165 transfected clones, which could be distinguished from the endogenous form after NcoI digestion.
Measurement of the VEGF content by radioreceptorassay showed that the constitutive expression of human V165 mRNA was translated in a functional product (control and V165-transfected cells released in their conditioned medium 9 and 70 ng/48 h/10 6 cells of VEGF respectively).
It has been previously shown by RT ± PCR that normal RCS RPE cells express FGF2 mRNA (Malecaze et al., 1993) . We con®rmed by Western blot that they were actively transcribed. It appeared that normal and Cc1 cells express several isoforms of immunoreactive FGF2, migrating as a doublet of 18 and 22 kDa bands and an additional 32 kDa molecular species (Figure 3 ). The intensity of the 22 kDa isoform immunoreactivity was twice that of the 18 kDa in transfected and not transfected cells.
Stable expression of V165 induces a growth advantage and cell transformation in the presence of FGF-2
Our previous studies have evidenced that VEGF acts as an autocrine growth factor for human RPE cells (Guerrin et al., 1995) . To determine whether the eightfold increase of bioactive VEGF modi®ed the growth characteristics of rat RPE cells, proliferation assays were performed in monolayers and in soft agar. In the presence of 6% serum the doubling time of control transfected clone Cc1 was 104 h. Although Cc1 cells secrete 0.7 ng/ml of VEGF in the culture medium, exogenously added VEGF (2 ± 20 ng/ml) Figure 2 Expression of bioactive VEGF in Cc1 and V165a8 cell lines. Cc1 and V165a8 con¯uent monolayers were exposed to serum free medium supplemented with 5 mg/ml of insulin and 10 mg/ml transferrin for 48 h and the cells were counted. VEGF content in the conditioned medium was determined by radioreceptorassay as described in the text. Results are expressed in comparison with recombinant human VEGF. The experiment was repeated twice for each clone, in triplicate, with similar results induced a moderate increase of Cc1 cell number corresponding to a reduction of the doubling time to 85 h. The doubling time of V165a8 was 38 h ( Figure  4 ) which was not modi®ed by exogenously added VEGF. FGF2 stimulated the proliferation of untransfected RCS, Cc1 and V165a8 as a function of the dose added. Dose-response curves allowed the calculation of ED50 which were not statistically dierent (1.2, 2.5 and 0.9 ng/ml respectively). The cell number increase obtained after 6 days in the presence of FGF2 was similar (average 170%) for RCS, Cc1 and V165a8. Moreover, typical of transformed cells, V165a8 lost its contact inhibition in the presence of FGF2, grew in multilayers and even formed foci (data not shown). The clones were tested for growth in soft agar to provide further evidence of FGF2-dependent cell transformation. No proliferation was observed in control transfected cells. Clones transfected with V165 were found to be capable of growth in this medium, only when incubated in the presence of FGF2 ( Figure 5 ). The number of colonies obtained with V165a8 and V165b3 corresponded to a colony forming eciency of 2 ± 4%.
FGF-2 induced cell transformation of V165 clones is associated with enhanced FGFR-1 expression
Cell transformation upon FGF-2 addition prompted us to examine the expression of the FGF receptors in V165 transfected cells. The expression of FGFR-1 was ®rst analysed by Northern blot of total RNA. FGFR-1 mRNA was identi®ed as an abundant major transcript of 4.5 kb in V165-transfected cells but was almost undetectable in control transfected clones ( Figure 6 ). The equal loading of the dierent lanes was checked by a second hybridization with a b actin probe. In contrast, the expression of FGFR-2 mRNA was extremely low as assessed by Northern blot analysis and no dierence could be detected between control and V165-transfected cells (data not shown).
The FGFR-1 gene encodes a large group of splicing variants in the intracellular, autophosphorylation and substrate interaction domains (for a review, see . Kinase-defective isoforms (FGFR-1, type 2) may act as dominant negative suppressors of FGFinduced activity (Shi et al., 1993) . To ensure that the FGFR-1 mRNA upregulation observed in V165 transfected cells was associated with potentially active signal transduction complexes, we analysed the intracellular domain by PCR ampli®cation (primers Figure 3 Expression of FGF2 in RCS, Cc1 and V165a8 cell lines. Con¯uent RPE cells were collected by scraping in PBS supplemented with 5 mg/ml of each leupeptin, aprotinin and pepstatin and an aliquot was counted in a Coulter counter. The cells were washed by centrifugation and the pellet lysed in RIPA buer (0.1% SDS, 1% cacodylate, 1 mM EDTA in 10 mM phosphate buer pH 7.4). The cell lysate corresponding to 2610 5 cells was denatured, reduced and resolved on a 15% SDS ± PAGE electrophoresis. Gels were transferred on nitrocellulose ®lters and processed as described in the text. The sizes of molecular weight markers are indicated on the right Figure 4 Growth curves of transfected RPE cells on plastic. Cells were plated at 10 4 per well in 12-well plates (day 71). On the following day (day 0) the cells were counted and incubated in the presence (closed symbols) and absence (open symbols) of FGF-2 (10 ng/ml). At the indicated time, cells were trypsinized and counted. The results represent the average of triplicate cultures and are representative of two experiments. When not indicated, error bars were smaller than symbol width. Growth assays were also performed with the other clones corresponding to each VEGF construction and similar results were obtained III and IV, Figure 7a ). One DNA fragment of approximately 700 base pairs was ampli®ed from all the clones tested, (Figure 7b ) and its identity with FGFR-1 cDNA con®rmed by restriction enzyme digestion (data not shown). This analysis revealed that the high FGFR-1 expression level induced by V165 corresponded to type 1 FGFR-1, although the presence of the type 2 could not be excluded. The results also demonstrated that control RPE cells express a low level of FGFR-1 mRNA in vitro which could be detected after PCR ampli®cation, but which was not revealed by Northern blot analysis.
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Most cultured cells express both the two (FGFR-1b) and the three (FGFR-1a) immunoglobulin-like FGFR-1 isoforms (Bernard et al., 1991) . To distinguish between these two extracellular variants, PCR ampli®cation of FGFR-1 cDNA was performed with the 5' primer V located upstream of the start codon and the 3' primer VI located just before the transmembrane region ( Figure 6a ). We ampli®ed two fragments of 1.15 kb and 0.88 kb corresponding to the FGFR-1a and FGFR-1b, respectively. Figure 7c shows that there is no change in the b/a ratio associated with FGFR-1 overexpression in V165-transfected cells, as compared to control cells.
Enhanced-FGFR-1 expression in V165-transfected cells was further con®rmed by cross-linking experiments. Two cross-linked complexes with estimated molecular masses of 160 and 145 kDa were visualized in all cells analysed (Figure 8) . Subtraction of the molecular mass of FGF-2 from the size of the crosslinked complexes yields estimated molecular masses of 140 and 125 kDa, consistent with that of the three and the two immunoglobulin-like FGFR-1 isoforms, respectively. Excess unlabeled FGF-2 blocked formation of these cross-linked complexes (data not shown). V165-transfected clones, exhibited a dramatic increase in FGFR expression as compared to control transfected clones (note that tenfold less V165a8 cells than Cc1 cells were subjected to electrophoresis). Treatment of the cells with protein A puri®ed anti-FGF2 or anti-VEGF IgG did not modify cell surface receptors bioavailability for FGF2, suggesting that the increase of FGFR1 expression was not regulated by secreted FGF2 or VEGF.
Discussion
Vascular endothelial growth factor exhibits special features clearly distinct from all other known angiogenic peptides. In contrast to TGF-b, which mainly acts through monocyte chemotaxis (Wahl et al., 1987) , VEGF is categorized as a direct angiogenic factor, as it stimulates endothelial cell proliferation and migration in the absence of any other cell type (PloueÈ t et al., 1989) . Unlike FGF-1 or FGF-2 (Jaye et al., 1986; Abraham et al., 1986) , VEGF is a secreted peptide with a typical NH 2 -terminal signal sequence (Leung et al., 1989; Keck et al., 1989; Conn et al., 1990b) . The mitogenic activity of VEGF is mainly restricted to vascular endothelial cells. In vivo, VEGF induces angiogenesis of both microvascular and arterial vessels, as recently shown in the rabbit ischemic hind limb model (Takeshita et al., 1994) . VEGF can also induce vascularized proliferative lesions in vivo when constitutively expressed CHO cells injected in nude mice . The spatial distribution of VEGF binding sites in adult body sections is correlated with the presence of the von Willebrand factor, an endothelial speci®c marker (Jakeman et al., 1992) .
However, VEGF acts as an autocrine mitogenic factor for IL-2 dependent lymphocytes (Praloran et al., 1991) and hair dermal papilla cells (Lachgar et al., 1996) and a chemotactic factor for non vascular cells such as monocytes (Clauss et al., 1990) , lens epithelial and corneal endothelial cells , melanoma cells (Gitay-Goren et al., 1993) , or osteoblasts (Midy and PloueÈ t, 1994) . In human retinal pigment epithelial (RPE) cells, we also evidenced high anity binding sites for VEGF, associated with mitogenic and chemotactic eects. These cells express the mRNA coding for the two VEGF receptors, KDR and¯t-1 (Guerrin et al., 1995) . In agreement with Adamis et al. (1993) , we found that cultured RPE cells express the 121 and 165 amino acid forms of VEGF. As anti-VEGF antibodies inhibit the proliferation and migration of RPE cells, these data strongly suggest that VEGF is an autocrine growth factor for such cells. Lysates of human post-mortem RPE cells contain VEGF (Adamis et al., 1993) . We also found V121 and V165 mRNA in ex vivo sheets of rat adult pigment epithelium (M Guerrin, unpublished data). The presence of both VEGF and its receptors in these non proliferating cells, suggests that this factor might be necessary for maintenance of the integrity of pigment epithelium, as previously suggested for quiescent vascular endothelium Monacci et al., 1993) . In addition VEGF, also described as Vascular Permeability Factor (Senger et al., 1983; Keck et al., 1989) , might regulate the permeability of pigment epithelium.
In the present article, we established clones of rat RPE cells, which stably express the 165 amino acid form of VEGF. Overexpression of VEGF induces distinct eects on cell growth: (1) the proliferation rate on plastic is increased approximately twofold and associated with increased saturation density; (2) these cells are more sensitive to the mitogenic eect of FGF-2; (3) in the presence of FGF-2, they become multilayered and form foci; (4) they form colonies in soft agar, only in the presence of FGF-2. These data establish ®rst, that overexpression of VEGF provides a growth advantage to RPE cells and secondly, that a synergy exists with FGF-2 in promoting a transformed phenotype of the cells. In contrast, CHO cells overexpressing VEGF do not display any growth advantage in vitro (Ferrara et al., 1993b) . This discrepancy could be related to the absence of VEGF binding sites on CHO cells. This Interactions between VEGF and other growth factors have already been described. EGF stimulates VEGF production in glioblastoma cells (Goldman et al., 1993) , whereas TGF-b induces VEGF mRNA and protein in ®broblastic and epithelial cells (Pertovaara et al., 1994) . VEGF synthesis is also increased by FGF-2 in rat vascular smooth muscle cells . In these cases, however, the proliferation of these VEGF producing cells is not aected by this factor so that the interactions occur by paracrine mechanisms. In contrast, a potent synergism between VEGF and FGF-2 has already been described on collagen gel cultured endothelial vascular cells that express receptors for both FGF-2 and VEGF but not the VEGF protein (Pepper et al., 1992; Goto et al., 1993) . This synergy only seems eective in three dimensional culture conditions since we could only evidence additive proliferative eects on monolayer cultured capillary endothelial cells (PloueÈ t and Moukadiri, 1990) . It is tempting to speculate that VEGF and FGF-2 synergise by controlling the formation of a local matrix that facilitates proliferation in semi solid medium.
Our results with RPE cells demonstrate that VEGF and FGF-2 can cooperate to induce cell transformation. The concept of growth factor synergistic eects on cell transformation is clearly established. PDGF B cooperates with EGF and TGF-b to induce NRK®broblast growth in soft-agar (Assoian et al., 1984) . RPE cells express FGF receptors and respond to the mitogenic eect of FGF-2 (Leschey et al., 1990) . Among the four receptors, FGFR-1 and 2 have a high anity for FGF-2 (Dionne et al., 1990) . In contrast, FGFR-3 preferentially binds FGF-1 (Ornitz and Leder, 1992) , and FGFR-4 binds FGF-1 with high anity but shows low anity for FGF-2 (Vainikka et al., 1992) . Cell transformation upon FGF-2 addition has been described in ®broblasts overexpressing FGFR-1 (Bernard et al., 1991) . As a ®rst step to elucidate VEGF and FGF-2 synergy in our model, we analysed FGF receptor mRNA. Our results indicate that V165-transfected cells overexpress FGFR-1 mRNA when compared to control-transfected cells. The major transcript of 4.5 kb that we detected corresponds to the mRNA coding for the complete receptor. PCR ampli®cation evidenced FGFR-1 isoforms containing the complete intracellular domain. Moreover, the PCR ampli®cation of the extracellular domain demonstrated that RPE cells express both the a and b (3 and 2 Ig-like domains, respectively) isoforms of FGFR-1, and this was not modi®ed by V165 transfection. Cross-linking experiments con®rmed that FGF-2 binding sites were dramatically enhanced on V165-transfected cell surface. In contrast, FGFR-2 mRNA expression was low in control as well as in VEGF-transfected cells. Since FGF-2 is produced by RPE cells (Schweigerer et al., 1987) , its binding to the overexpressed FGFR-1 might account for the growth advantage of V165-transfected cells, by autocrine mechanism. Experiments using neutralizing anti-FGF2 or anti-VEGF antibodies showed that neither FGF2 nor VEGF had to be released in order to induce cell transformation. Such a phenomenon is clearly reminiscent of the observation of Bikfalvi et al. (1995) demonstrating that overexpression of high molecular forms of FGF2 trigger cell proliferation and anchorage-independent growth even when the bioavailability of functional FGF receptors had been inhibited by antibody addition or constitutive expression or dominant negative FGF receptor. However in these transfected cells high molecular FGF2 was not increased as compared to wild-type RPE. Although RPE cells already produce FGF-2, exogenous addition of this factor still induces signi®cant eects on the cells. Endogenous FGF-2 could be present in concentrations insucient to trigger cell transformation. Alternatively, this could be related to dierent bioavailabilities or transduction pathways between endogenous and exogenous FGF-2.
In summary, the data reported here represent the ®rst observation that VEGF overexpression contributes to cell transformation.
Materials and methods
Construction of expression vectors
The fragment XbaI/SacI of pUC165, a generous gift from J Abraham (Tisher et al., 1989) , corresponding to the full length coding sequence of human 165 VEGF cDNA, was subcloned into the bicistronic eucaryotic expression vector pR-EN, generously provided by H Prats (Patry et al., 1994) . In this construct (pR-EN-V165), the VEGF cDNA and the Neo gene are placed downstream of a cytomegalovirus promoter element. Control vector contained bacterial CAT cDNA in place of VEGF (pREN-CAT).
Cell culture and transfection
Rat RPE cell culture was performed by modi®cation of published methods (Edwards, 1977) . Brie¯y intact eyes from 8 ± 10-day-old rats of the RCS strain (originally supplied by the NIH Small Animal Section, Bethesda, MD) were incubated for 1 h in D/F12 medium containing 0.2% trypsin and 500 U/ml collagenase IA. The dissection of the RPE sheets was carried out at 506 under a dissecting microscope and extreme care was taken to select only those sheets free of contamination by any other cell types. The pooled RPE sheets were further trypsinized and gently triturated to obtain single cell suspensions. The RPE cells were seeded into collagen-coated dishes in D/F12 medium supplemented with 18% fetal calf serum (FCS), 2% adult rat serum and antibiotics, and expanded under the same conditions. Cytokeratin immunocytochemistry was performed to control the epithelial phenotype of the cultures.
Cells at passage 4 were plated on 100 mm collagen-coated dishes (2610 6 per dish) and transfected by the calcium phosphate method. Selection was performed for 2 weeks with G418 (Sigma) at 0.4 mg/ml with a medium change every 4th day. Colonies were picked with Pasteur pipettes and expanded in individual dishes in the same selection medium for 2 additional weeks. Two representative clones were analysed for each type of transfection, with comparable results: V165b3, V165a8; p-R-EN-CAT clones: Cc1, Cc2.
Cell proliferation assays
Cell proliferation on plastic was assessed by seeding RPE cells into 12-well cluster plates (10 4 cells/well) in D/F12 medium containing 4% FCS and 2% rat serum. On the following day, triplicate wells were counted (day 0), to control plating eciency. The cells were then cultured with or without 10 ng/ml human recombinant FGF-2 (a generous gift from H Prats), added every other day. The cells were trypsinized and counted in a cell counter (Coulter Counter, Coultronics, France) at the indicated times. The data were ®tted to exponential growth curves, using the Inplot program (GraphPad, San Diego, CA). D/F12 (1 ml) supplemented with 4% FCS and 2% rat serum and containing 0.8% Bacto agar (Gibco BRL) was added to 35 mm dishes and allowed to solidify for the soft agar growth determination. Cells were trypsinized, counted and suspended in 1 ml of the same medium containing 0.4% agar, at a density of 5610 3 cells/dish in triplicate. After solidi®cation, 0.5 ml of the same medium either containing FGF-2 (20 ng/ml) or not was added to the agar layer. The cultures were maintained in humidi®ed incubators (378C) in a 5% CO 2 /95% air environment for 12 days and FGF-2 was added every 4 days. Viable colonies were stained by the addition of 1 ml per dish of MTT (dimethylthiazolyldiphenyltetrazolium bromide, Sigma) stain (10 mg/ml) followed by incubation overnight at 378C. Stained colonies with a diameter exceeding 100 mm were counted using a colony counter (Accucount).
RNA extraction and Northern blot analysis
The one-step acid guanidinium isothiocyanate/phenolchloroform extraction method was used for RNA extraction (Chomczkinski and Sachi, 1987) . For Northern blot analysis, total RNA (20 mg) was run on a 1.2% formaldehyde agarose gel, blotted on to a Hybond-N nylon membrane (Amersham) by capillary transfer and u.v.-cross-linked. Hybridization was performed with a 2.74 kb EcoRI ± EcoRI fragment of the human FGFR-1 cDNA, nt 589 to 3337, kindly provided by L Claesson-Welsh (WennstroÈ m et al., 1991) or with a 2.3 kb fragment of the human FGFR-2 cDNA, nt 1 to 2291 (Houssaint et al., 1990) . These probes were 32 P-labeled by using a multiprime DNA labeling system (Promega). RNA blots were reprobed with a mouse b actin cDNA as a control for equal lane loading and transfer.
First-strand cDNA synthesis and PCR assays
The ®rst-strand cDNA was synthesized from 4 mg of total RNA with a random primer and Moloney murine leukemia virus reverse transcriptase (Superscript Preampli®cation system, Gibco BRL). Negative controls consisting of reverse transcriptase reactions without RNA template were included and used for each subsequent PCR ampli®cation. PCR was performed in a 50 ml volume containing 1 ml of the cDNA reaction mixture, 250 mM each of the four deoxynucleoside triphosphates, 50 pmol of each primer and 0.5 U of Taq polymerase (Appligene). Thirty cycles, consisting of denaturation at 948C for 1 min, annealing at 568C for 1 min, and extension at 728C for 1 min were performed. The authenticity of the ampli®ed products was veri®ed by agarose gel electrophoresis with appropriate markers (1 kb ladder, BRL) and by restriction enzyme digestion. The unique NcoI enzyme restriction site located in position 139 of the dierent human but not rat VEGF cDNAs was used to ascertain the transcription of the human VEGF sequence in the rat RPE cells.
PCR primers
Gene-speci®c primers were designed from published sequences and are listed in Table 1 in the 5' to 3' direction.
Southern blots
Products of the ampli®cation of cDNA fragments corresponding to the extracellular region of FGFR-1 were separated by electrophoresis on agarose gels and transferred to a nylon ®lter (Hybond N + ), using the alkalin transfer protocol given by the manufacturer (Amersham), with a VacuGene apparatus (Pharmacia, LKB). Blots were hybridized with the 32 P-labeled 27.4 kb fragment of the human FGFR-1 cDNA.
Growth factor binding assays VEGF and FGF-2 were iodinated by chloramine T treatment and puri®ed by heparin sepharose anity chromatography (speci®c activities averaged 1.2 and 0.4610 4 c.p.m./ng respectively). VEGF content was measured with a radioreceptorassay using fetal bovine aortic endothelial cells (FBAE) as target cells as already described (PloueÈ t and Moukadiri, 1990) . Brie¯y 1 ng of iodinated VEGF and 10 ml of the desired concentrations of VEGF or conditioned medium were incubated with subcon¯uent FBAE cells for 3 h at 48C. After three washes with PBS, the cells were lysed with 0.2 M NaOH and the radioactivity counted. Results are expressed by comparison with a standard curve of recombinant VEGF.
Cross-linking was performed as described (Neufeld and Gospodarowicz, 1985) . Cells were grown to subcon¯uence and incubated or not with 100 mg/ml of anti-FGF2 (PloueÈ t et al., 1989) or anti-VEGF (Guerrin et al., 1995) IgG for 24 h at 378C. The cultures were then washed twice in ice-cold binding medium (DMEM-20 mM HEPES, pH 7.3-gelatin 1 mg/ml) and incubated in the same medium with 10 ng/ml [ 125 I]FGF-2. A 100-fold excess (1 mg/ml) of unlabeled FGF-2 was included as a computer in parallel experiments. The binding was performed for 2 h at 48C with gentle agitation. After two washes in PBS, cross-linking was performed with disuccinimidyl suberate (DSS; Pierce) (0.15 mM in PBS) for 15 min at room temperature and stopped with 0.2 M glycin pH 7.4. The cell pellet was resuspended in 16sample buer, reduced (bmercaptoethanol 0.05 M), and boiled. Cells in parallel cultures were counted and samples corresponding to 10 5 cells per lane were loaded on a SDS-7% polyacrylamide gel. Gels were stained with Coomassie Blue and autoradiographed.
FGF2 Western blot
RPE cells were grown to con¯uence, collected by scraping in PBS supplemented with 5 mg/ml of each leupeptin, aprotinin and pepstatin and an aliquot was counted in a Coulter counter. The cells were washed by centrifugation and the pellet lysed in RIPA buer (0.1% SDS, 1% cacodylate, 1 mM EDTA in 10 mM phosphate buer pH 7.4). The soluble material was collected by centrifugation, mixed with sample buer, reduced (b-mercaptoethanol 0.05 M), boiled and resolved on a SDS-15% polyacrylamide gel. Gels were transferred on nitrocellulose ®lters. The ®lters were stained with Ponceau red, treated with 5% non fat milk in TBST (10 mM Tris, 150 mM NaCl, 0.05% Tween 20, pH 7.4) and incubated with 1 mg/ml of anti-FGF2 antibody (Oncogene Science). Immunoreactive proteins were detected by incubation with 1/20 000 dilution of peroxidase-conjugated anti rabbit IgG, followed by development with luminol substrate.
